"The political, regulatory, and marketing stories of the pharmaceutical industry in 2012 remain to be told, but the upcoming elections, the growing strength of generics and biosimilars, the explosive demand of emerging markets, and the ubiquity of social media are all expected to play leading roles."
Click here to continue reading MedAdNews magazine's take on the fate of the pharmaceutical industry in 2012, featuring insights from HRM's Scott Weintraub.
